GUJTHEM Stock Overview

Engages in the manufacture of pharmaceuticals and medicinal chemicals in India. More details

GUJTHEM fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	3/6
Financial Health	6/6
Dividends	1/6

Risk Analysis

Shares are highly illiquid

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

My Notes

Capture your thoughts, links and company narrative

Gujarat Themis Biosyn Limited Competitors

Morepen Laboratories

BSE:500288

₹27.1b

RPG Life Sciences

NSEI:RPGLIFE

₹35.9b

Gufic Biosciences

BSE:509079

₹36.0b

TTK Healthcare

BSE:507747

₹16.9b

Price History & Performance

Summary of share price highs, lows and changes for Gujarat Themis Biosyn
Historical stock prices
Current Share Price	₹262.33
52 Week High	₹281.69
52 Week Low	₹208.00
Beta	0.17
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	7.75%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	GUJTHEM	IN Pharmaceuticals	IN Market
7D	12.3%	-0.1%	-1.0%
1Y	n/a	7.0%	-3.4%

Return vs Industry: Insufficient data to determine how GUJTHEM performed against the Indian Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how GUJTHEM performed against the Indian Market.

Price Volatility

Is GUJTHEM's price volatile compared to industry and market?
GUJTHEM volatility
GUJTHEM Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	6.9%
Market Average Movement	6.8%
10% most volatile stocks in IN Market	9.5%
10% least volatile stocks in IN Market	4.5%

Stable Share Price: GUJTHEM's share price has been volatile over the past 3 months compared to the Indian market.

Volatility Over Time: Insufficient data to determine GUJTHEM's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1981	159	Guha Guhathakurata	www.gtbl.in

Gujarat Themis Biosyn Limited engages in the manufacture of pharmaceuticals and medicinal chemicals in India. The company offers bulk drugs on job work basis in India. Its products include Rifamycin-S, an intermediate for the treatment of tuberculosis; Rifamycin-O; and Lovastatin.

Gujarat Themis Biosyn Limited Fundamentals Summary

How do Gujarat Themis Biosyn's earnings and revenue compare to its market cap?
GUJTHEM fundamental statistics
Market cap	₹28.60b
Earnings (TTM)	₹526.59m
Revenue (TTM)	₹1.55b

54.3x

P/E Ratio

18.4x

P/S Ratio

Is GUJTHEM overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GUJTHEM income statement (TTM)
Revenue	₹1.55b
Cost of Revenue	₹607.43m
Gross Profit	₹943.32m
Other Expenses	₹416.73m
Earnings	₹526.59m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	4.83
Gross Margin	60.83%
Net Profit Margin	33.96%
Debt/Equity Ratio	1.5%

How did GUJTHEM perform over the long term?

See historical performance and comparison

Dividends

0.3%

Current Dividend Yield

3%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/03/06 22:32
End of Day Share Price	2025/03/06 00:00
Earnings	2024/12/31
Annual Earnings	2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Gujarat Themis Biosyn Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Anil Burra	FirstCall Research